Sharemaestro Newsreel

Collegium Pharmaceutical falls 13% on weak revenue guidance

Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares dropped 13.5% after reporting Q2 results that missed revenue expectations and issuing weaker-than-expected full-year guidance. Although adjusted EPS beat estimates, revenue fell short, and the company lowered its 2026 revenue and adjusted EBITDA forecasts. The decline was primarily attributed …

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

Bausch + Lomb (NYSE/TSX: BLCO) announced changes to its Board of Directors, with four new appointments effective August 5, 2026, at the request of majority owner Bausch Health Companies Inc. The company also reaffirmed its full-year 2026 guidance for revenue between $5.440 billion and …

Amylyx Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary

Amylyx Pharmaceuticals, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters via TradingView News, indicates that this report provides key financial results for the company during that period.

Sonoma Pharmaceuticals, Inc. Q1 2027: Revenue $6.41M, EPS $(0.09) — 10-Q Summary

Sonoma Pharmaceuticals, Inc. reported Q1 2027 results with revenue increasing to $6.41 million, a 60% year-over-year rise, and a narrowed net loss of $0.33 million, improving from the prior year. This growth was driven by a 141% increase in U.S. sales, led by OTC …

Sonoma U.S. Revenue Climbs 141%; First-Ever Positive Adjusted EBITDA

Sonoma Pharmaceuticals (NASDAQ: SNOA) reported a significant 60% year-over-year increase in fiscal Q1 2027 revenue to $6.4 million, driven by a 141% surge in U.S. sales and global growth. The company achieved its first-ever positive adjusted EBITDA of $0.05 million and expanded its gross …

Earnings Flash (CRON) Cronos Group Inc. Reports Q2 Revenue $53.0M, vs. FactSet Est of $44.2M

Cronos Group Inc. (CRON) reported strong second-quarter results, with revenue reaching $53.0 million, significantly surpassing FactSet's estimate of $44.2 million. This positive performance led to a rise in Cronos Group shares. The company, a global cannabinoid firm, continues to focus on advancing cannabis research, …

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

Zoetis (ZTS) Surpasses Q2 Earnings Estimates

Anika Therapeutics (NASDAQ:ANIK) Director Purchases 1,000 Shares

Anika Therapeutics Director Gary Fischetti purchased 1,000 shares of ANIK stock for $20.75 each, increasing his direct ownership to 53,015 shares. This transaction follows strong quarterly earnings where Anika reported $0.42 EPS and $32.61 million in revenue, both exceeding analyst expectations. Despite institutional investors …

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) announced that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This comes after its Class A ordinary shares closed at or above $1.00 for 10 consecutive business days from July 20 to …

RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating

RBC Capital has adjusted its price target for BioCryst Pharmaceuticals (BCRX) to $13, down from $14, while maintaining an Outperform rating on the stock. This revision comes amidst recent company news, including the discontinuation of internal drug discovery programs and a positive earnings report …

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Ironwood Pharmaceuticals reported strong second-quarter 2026 results, leading the company to raise its full-year financial guidance for LINZESS U.S. net sales, total revenue, and adjusted EBITDA. The company also announced the initiation of the confirmatory Phase 3 STARS-2 trial for apraglutide in short bowel …

Haleon rises Thursday, outperforms market

Haleon PLC (HLN) shares rose by 1.34% to £3.71 on Thursday, outperforming the broader market as the FTSE 100 Index (UKX) fell by 0.19%. The company's stock closed 10.93% below its 52-week high of £4.16, which was reached on February 18th. This increase occurred …

Earnings Flash (LNTH) Lantheus Holdings, Inc. Posts Q2 Adjusted EPS $1.55 per Share, vs. FactSet Est of $1.30

Lantheus Holdings, Inc. (LNTH) reported Q2 adjusted EPS of $1.55 per share, surpassing the FactSet estimate of $1.30. The company also announced its Q2 revenue of $388.2 million, exceeding the FactSet estimate of $363.2 million. Additionally, Lantheus suspended its previously issued full-year 2026 financial …

BioCryst Pharmaceuticals (BCRX) Stock Stalls Despite Profit Surge And ORLADEYO Strength

BioCryst Pharmaceuticals (BCRX) reported a significant profit surge in Q2 2026, driven by strong ORLADEYO revenue and a European licensing deal, yet its stock remained largely unchanged. While ORLADEYO shows real patient uptake and the company has solid liquidity, concerns remain about its reliance …

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Pharmaceutical, Inc. reported strong Q2 2026 financial results, with net revenues up 6% year-over-year to $199.9 million, driven by a 41% increase in JORNAY PM revenue and the successful acquisition and initial sales of AZSTARYS. The company updated its full-year 2026 financial guidance, …

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira BioSciences announced the publication of positive two-year results from its Phase 1 clinical trial for PCRX-201, an investigational gene therapy for knee osteoarthritis, in the Annals of the Rheumatic Diseases. The study found that a single intra-articular injection of PCRX-201 was well-tolerated and …

BioAge Labs Reports Q2 2026 Results, Doses First Patient in QUELL-CV and Advances BGE-102 Clinical Development

BioAge Labs announced its Q2 2026 results, reporting a net loss of $26.1 million, but also significant progress in its clinical trials. The company dosed the first patient in its QUELL-CV Phase 2 trial for BGE-102, targeting inflammation and cardiometabolic biomarkers, with topline data …

ZYBT Stock Whipsaws As Speculative Trading Frenzy Unwinds

Zhengye Biotechnology Holding Limited (ZYBT) stock experienced extreme volatility, whipsawing significantly due to speculative trading. After a massive 1,047% surge, the stock plunged by over 70% and continued to show significant premarket swings, indicating a classic boom-and-bust pattern driven by momentum rather than fundamentals. …

Cronos Group Reports 2026 Second Quarter Results

Cronos Group (NASDAQ: CRON) announced strong second-quarter 2026 results, achieving record net revenue, gross profit, and Adjusted EBITDA. The company reported a 58% year-over-year increase in net revenue to $53.0 million and a 96% increase in gross profit to $28.5 million. This growth was …

Prestige Consumer Healthcare (PBH) Q1 Earnings and Revenues Surpass Estimates

ZOETIS ($ZTS) Releases Q2 2026 Earnings

BioCryst Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BCRX) 2026-08-06

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported strong Q2 results, with ORLADEYO revenue increasing 10% year-over-year and pediatric oral-pellet shipments commencing. The company maintained its 2026 ORLADEYO revenue outlook and reduced its non-GAAP operating cost guidance by ending internal drug discovery. BioCryst also completed enrollment for its …

Earnings Flash (VTRS) Viatris Inc. Posts Q2 Adjusted EPS $0.69 per Share, vs. FactSet Est of $0.60

Viatris Inc. (VTRS) reported Q2 adjusted EPS of $0.69 per share, surpassing the FactSet estimate of $0.60. The company also announced Q2 revenue of $3.76 billion, exceeding the FactSet estimate of $3.68 billion.

Prestige Consumer Healthcare (NYSE: PBH) awards director 2,981 RSUs

Prestige Consumer Healthcare (NYSE: PBH) director Dawn M. Zier was granted 2,981 restricted stock units (RSUs) as part of the company's director compensation program. The RSUs, valued at $155,000 based on a $52.00 closing stock price, will vest on the first anniversary of the …

The only FDA-approved dry-eye nasal spray is set to join Harrow later in 2026

Harrow has entered an agreement to acquire global rights to TYRVAYA, the sole FDA-approved nasal spray for dry eye disease, from Viatris. The deal, valued at up to $100 million ($30 million upfront cash and up to $70 million in sales-tied milestones), is expected …

Form 8K Harrow Health Inc For: 6 August By Investing.com

Harrow Health Inc. (HROW) filed a Form 8K on August 6, 2026. This SEC filing typically indicates significant events that shareholders should know about. The article provides the title of the filing and its publication date, without detailing the specific content of the 8K.

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow has acquired global rights to TYRVAYA® (varenicline solution) nasal spray from Viatris Inc. for up to $100 million. This acquisition significantly expands Harrow's dry eye portfolio, complementing its VEVYE franchise with a differentiated, drop-free treatment option for dry eye disease. The deal is …

Kamada (KMDA) director Uri Botzer receives 30,000 stock options

Kamada Ltd. director Uri Botzer was granted 30,000 Employee Stock Options to purchase Ordinary Shares at an exercise price of $7.52 per share. These options will vest in four equal annual installments and are exercisable for 10 years from the grant date. The award …

BFRI Q2'26 Earnings: EPS estimate is (0.10) USD

Biofrontera Inc. (BFRI) is scheduled to release its Q2'26 earnings on August 7th. Analysts estimate the company will report revenue of $9.50 million and an earnings per share (EPS) of ($0.10) for the quarter. The article also provides historical reported and estimated revenue and …

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Inc. announced strong second-quarter 2026 financial results, with total revenues of $3.8 billion, a 5% reported growth, and Adjusted EBITDA of $1.2 billion, up 8% operationally. The company raised its 2026 financial guidance midpoints, returned approximately $550 million to shareholders, and reduced its …

Earnings Flash (UTHR) United Therapeutics Corporation Reports Q2 Revenue $783.3M, vs. FactSet Est of $804.6M

United Therapeutics Corporation (UTHR) reported its Q2 revenue at $783.3 million, falling short of FactSet's estimate of $804.6 million. This earnings flash highlights the pharmaceutical company's financial performance for the second quarter, providing key revenue figures against analyst expectations.

Earnings call transcript: United Therapeutics posts Q2 2026 EPS beat, revenue miss

United Therapeutics reported mixed Q2 2026 results, beating EPS estimates with $7.27 per share but missing revenue forecasts at $783.3 million. The stock fell in premarket trading as investors focused on the sales miss and cautious near-term outlook despite pipeline progress in IPF, PAH, …

Tilray Brands Expands THC Beverage Innovation with the Launch of Mollo Lite Blackberry Lemon Seltzer Multi-Pack

Tilray Brands (Nasdaq: TLRY; TSX: TLRY) has launched Mollo Lite Blackberry Lemon Seltzers 4-Pack in Canada, marking the first light THC beverage multipack under its Mollo brand. Each 355 mL can contains 2.5 mg THC and 5 mg CBG, targeting adult cannabis consumers seeking …

Takeda’s Orzeyful approved in US as first-in-class orexin treatment for narcolepsy Type 1

The FDA has approved Takeda's Orzeyful (oveporexton) as the first medication to directly address the loss of orexin signaling in Narcolepsy Type 1. Unlike previous treatments that only offered symptomatic relief, Orzeyful targets the underlying cause by activating the brain's orexin receptor 2 (OX2R). …

Bausch Health Holds About 87% as CEO Joins Bausch + Lomb Board

Bausch Health announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb, effective August 5, 2026. This appointment, along with three other new directors, was requested by Bausch Health, which indirectly holds approximately 87% of …